Company Overview
Alkermes plc operates as a biopharmaceutical entity dedicated to the research, development, and commercialization of pharmaceutical products designed to address unmet medical needs for patients across the United States, Ireland, and international markets. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized therapeutic compounds rather than mass-market commodities. In terms of scale, Alkermes plc holds a market capitalization of $4.73B and reports annual revenue of $1.48B based on trailing twelve-month data, while employing a workforce of 2050 individuals. These valuation and revenue figures indicate that the company maintains a significant position within its niche, possessing a substantial asset base relative to its operational footprint and industry peers.
Financial Health
The company reported a trailing twelve-month revenue of $1.48B and generated a net income of $241.66M, resulting in an EBITDA of $281.12M. The gap between the $1.48B revenue figure and the $241.66M net income reveals a substantial cost structure where operating expenses and taxes consume approximately 83.6% of total sales before reaching the bottom line. Despite the positive net income, the free cash flow stands at -$363,090,624, which indicates that the company is currently burning cash rather than generating liquidity from its operations. This negative cash flow suggests limited financial flexibility for capital expenditures or acquisitions without relying on external financing or asset liquidation. The company maintains a gross margin of 86.7%, reflecting high pricing power or low cost of goods sold typical in specialty pharmaceuticals. Operating margins are recorded at 15.1%, while profit margins reach 16.4%, indicating that the company retains a moderate portion of revenue after covering all operating costs and taxes. On the balance sheet, Alkermes holds $588.21M in cash against $70.00M in debt, supported by a debt-to-equity ratio of 3.85, which suggests a leveraged capital structure where equity is significantly smaller than the total debt burden. However, the current ratio of 3.55 demonstrates a conservative short-term liquidity position, as current assets are more than three times current liabilities, ensuring the ability to meet short-term obligations. Return on equity is 14.7% and return on assets is 7.0%, metrics that reveal management is generating moderate returns on the equity invested and the total asset base utilized.
Valuation Assessment
Alkermes plc trades with a trailing P/E ratio of 19.86 and a forward P/E of 13.71, where the significant difference between these two metrics implies that the market expects earnings to decline sharply in the future relative to current levels. The price-to-book ratio is 2.59, indicating that the stock is trading at a substantial premium over its book value, suggesting investors are pricing in future growth potential or intangible assets not captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 3.21 and an EV/EBITDA of 14.99 suggest the company is valued based on sales multiples that are high relative to the revenue decline observed, while the EV/EBITDA reflects earnings power adjusted for debt and cash. The 52-week high is $36.32 and the 52-week low is $25.17, placing the current trading range within a band where the stock has experienced notable volatility over the past year. The beta value of 0.49 indicates that the stock price is less volatile than the broader market, moving with roughly half the intensity of the overall index.
Growth & Income
Revenue growth year-over-year is -10.6% and earnings growth year-over-year is -67.0%, demonstrating that earnings are contracting at a much faster rate than revenue, which implies declining profitability per unit sold or significant one-time charges impacting the bottom line disproportionately. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available earnings back into the business or reduces debt rather than distributing cash to shareholders. This reinvestment strategy is necessitated by the negative free cash flow and the need to sustain operations during the period of earnings contraction. Overall, the growth and income profile reflects a company in a transitionary phase characterized by shrinking earnings, zero dividend distribution, and a high reliance on existing cash reserves to fund operations amidst negative cash flow.